EDAP TMS S.A. (FRA:EDA)

Market Cap	171.12M +129.0%
Revenue (ttm)	69.42M +60.7%
Net Income	-34.11M
EPS	-0.93
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	235
Open	3.620
Previous Close	3.740
Day's Range	3.620 - 3.620
52-Week Range	1.450 - 5.350
Beta	n/a
Analysts	Buy
Price Target	5.37 (+48.34%)
Earnings Date	Nov 5, 2026

About EDAP TMS

EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment re...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1979
• Employees: 289
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EDA

Financial Performance

In 2025, EDAP TMS's revenue was $70.53 million, an increase of 1.63% compared to the previous year's $69.40 million. Losses were -$29.25 million, 42.1% more than in 2024.

Financial numbers in USD

Analyst Summary

According to 2 analysts, the average rating for EDA stock is "Buy." The 12-month stock price target is €5.37, which is an increase of 48.34% from the latest price.

Price Target

€5.37

(48.34% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error